Equities

CardioComm Solutions Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
EKG:CVE

CardioComm Solutions Inc

Actions
Health CareMedical Equipment and Services
  • Price (CAD)0.01
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change0.00%
  • Beta-2.5591
Data delayed at least 15 minutes, as of Feb 12 2026 15:21 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CardioComm Solutions, Inc. develops advanced software, hardware and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. The Company’s proprietary device connectivity and ECG management technologies are used in medical, consumer, clinical research and telemedicine solutions for recording, transmission, viewing, analyzing, reporting and storage of ECGs. The Global ECG Management Solutions (GEMS) and GlobalCardio (Cloud-based GEMS) products are licensed worldwide to hospitals, ECG commercial reading services and physicians. It also holds Class II medical device clearances for the manufacture, marketing, and sales of personal ECG monitors direct to consumers. The products are marketed under the HeartCheck brand. It developed compatibility of the HeartCheck device to its GEMS and GlobalCardio based software to enable use of the device for remote ECG/arrhythmia monitoring services.

  • Revenue in CAD (TTM)386.53k
  • Net income in CAD-404.82k
  • Incorporated1989
  • Employees16.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Imaging Dynamics Co Ltd104.20k-1.07m465.05k23.00------4.46-0.1033-0.10330.0101-0.55250.56031.9522.58---573.96-200.65----65.0461.63-1,024.48-444.170.0054-0.6348-----39.16-37.85-44.96---29.84--
EvokAI Creative Labs Inc-12.98k-13.61m876.37k-----------1.93-1.93-0.0018-0.1751-0.0019-------194.40-1,742.96-206.27-3,585.36-----------69.67---------3,392.77------
CardioComm Solutions Inc386.53k-404.82k1.98m16.00------5.11-0.0021-0.00210.002-0.00291.311.482.97---137.51-20.56----87.2583.20-104.73-9.130.2344-11.998.47---39.90-9.65-99.92---10.07--
Therma Bright Inc75.23k-4.16m3.12m--------41.53-0.0729-0.07290.0013-0.02480.04060.17260.3653---224.22-203.01-69,250.66-507.5765.25---5,523.12-9,158.610.1182-0.6815----207.9084.25-77.17------
Zero Candida Technologies Inc-100.00bn-100.00bn3.43m----2.09----------0.0839----------------------------0.0174--------------
Kovo+Holdings Inc14.75m-8.67m4.43m--------0.3005-0.0541-0.05410.0923-0.05810.8026--33.43---47.17-----------58.77-----0.7981.60--5.45---25.26------
NuGen Medical Devices Inc589.43k-2.12m6.81m12.00------11.56-0.0092-0.00920.0026-0.03810.04610.783919.59---16.58---20.05--54.97---359.36--3.90--1.90--204.73--44.18------
Data as of Feb 12 2026. Currency figures normalised to CardioComm Solutions Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.